Documents

Oral Dosage Form New Animal Drugs; Tetracycline Hydrochloride Soluble Powder

Federal Register · Uncategorized Document · Apr 14, 1994

Under section 512(c)(2)(F)(iii) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360b(c)(2)(F)(iii)), these approvals do not qualify for exclusivity periods because their applications do not contain … Control of chronic respiratory disease (CRD or air-sac disease) caused by Mycoplasma gallisepticum and E. coli; control of infectious synovitis caused by M. synoviae susceptible to tetracycline.

Refugee Resettlement Program; Availability of Formula Allocation Funding for FY 1996 Targeted Assistance Grants for Services to Refugees in Local Areas of High Need

Federal Register · Notice · Jul 12, 1996

Comment: Six commenters recommended that ORR determine country eligibility on an annual basis instead of the proposed three-year eligibility period. … One commenter recommended that ORR allow for a 90-day application period; another commenter recommended that there be a 60-day application period or that there be fewer application requirements, Response

Medical Devices; Mammography Quality Standards Act of 1992; Inspection Fees

Federal Register · Notice · Jan 14, 1998

Submit written comments by March 16, 1998. … Request for Comments Although the MQSA does not require FDA to solicit comments on fee exemption, assessment and collection, FDA is inviting comments from interested persons in order to have the benefit

Evaporated Milk; Amendment of the Standard of Identity

Federal Register · Uncategorized Document · Apr 14, 1994

These data show that the yearly average milkfat content for all producers' milk, before standardization for beverage purposes, during the period 1970 to 1991 (Ref. 1) ranged between 3.64 percent and 3.68 … The Regulatory Flexibility Act requires that the agency analyze options for regulatory relief for small businesses.

Advisory Committee; Notice of Meeting

Federal Register · Uncategorized Document · Feb 2, 1994

brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time required to make their comments … This notice is issued under section 10(a)(1) and (2) of the Federal Advisory Committee Act (5 U.S.C. app. 2), and FDA's regulations (21 CFR part 14) on advisory committees.